Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days

I. Raßmann, H. Schrödel, T. Schilling, M. Zucchetti, A. Kaeser-Fröhlich, J. Rastetter, A. R. Hanauske

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days'. Together they form a unique fingerprint.

Medicine & Life Sciences